{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:37:10Z","timestamp":1790941030981,"version":"4.1.0"},"reference-count":100,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2011,11,2]],"date-time":"2011-11-02T00:00:00Z","timestamp":1320192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>A critical first step in a \u201crational vaccine design\u201d approach for hepatitis C virus (HCV) is to identify the most relevant mechanisms of immune protection. Emerging evidence provides support for a protective role of virus neutralizing antibodies, and the ability of the B cell response to modify the course of acute HCV infection. This has been made possible by the development of in vitro cell culture models, based on HCV retroviral pseudotype particles expressing E1E2 and infectious cell culture-derived HCV virions, and small animal models that are robust tools in studies of antibody-mediated virus neutralization. This review is focused on the immunogenic determinants on the E2 glycoprotein mediating virus neutralization and the pathways in which the virus is able to escape from immune containment. Encouraging findings from recent studies provide support for the existence of broadly neutralization antibodies that are not associated with virus escape. The identification of conserved epitopes mediating virus neutralization that are not associated with virus escape will facilitate the design of a vaccine immunogen capable of eliciting broadly neutralizing antibodies against this highly diverse virus.<\/jats:p>","DOI":"10.3390\/v3112127","type":"journal-article","created":{"date-parts":[[2011,11,2]],"date-time":"2011-11-02T12:58:41Z","timestamp":1320238721000},"page":"2127-2145","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Neutralizing Antibody Response to Hepatitis C Virus"],"prefix":"10.3390","volume":"3","author":[{"given":"Yong","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pathology, School of Medicine, Stanford University, Stanford, CA 94305, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Yong","family":"Keck","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Medicine, Stanford University, Stanford, CA 94305, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven K. H.","family":"Foung","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Medicine, Stanford University, Stanford, CA 94305, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2011,11,2]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2011, September 12). Initiative for vaccine research. Hepatitis C, Available online: http:\/\/www.who.int\/vaccine_research\/diseases\/viral_cancers\/en\/index2.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","article-title":"Global epidemiology of hepatitis C virus infection","volume":"5","author":"Shepard","year":"2005","journal-title":"Lancet Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1053\/j.gastro.2011.01.028","article-title":"The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: A new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending","volume":"140","author":"Pawlotsky","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/hep.24262","article-title":"Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus","volume":"53","author":"Pawlotsky","year":"2011","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0016-5085(99)70353-7","article-title":"Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C","volume":"117","author":"Gerlach","year":"1999","journal-title":"Gastroenterology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1084\/jem.194.10.1395","article-title":"Determinants of viral clearance and persistence during acute hepatitis C virus infection","volume":"194","author":"Thimme","year":"2001","journal-title":"J. Exp. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/nature04079","article-title":"Adaptive immune responses in acute and chronic hepatitis C virus infection","volume":"436","author":"Bowen","year":"2005","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0140-6736(76)90357-3","article-title":"Efficacy of prophylactic gamma-globulin in preventing non-A, non-B post-transfection hepatitis","volume":"1","author":"Knodell","year":"1976","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/infdis\/156.1.56","article-title":"Prevention of endemic icteric viral hepatitis by administration of immune serum gamma globulin","volume":"156","author":"Conrad","year":"1987","journal-title":"J. Infect. Dis."},{"key":"ref_10","first-page":"1245","article-title":"Prevention of post-transfusion non-A, non-B hepatitis by non-specific immunoglobulin in heart surgery patients","volume":"1","author":"Pineda","year":"1988","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0140-6736(85)91431-X","article-title":"Hepatitis B immune globulin to prevent non-A, non-B post-transfusion hepatitis","volume":"1","author":"Sugg","year":"1985","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/archinte.1997.00440350037004","article-title":"Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial","volume":"157","author":"Piazza","year":"1997","journal-title":"Arch. Intern. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"7792","DOI":"10.1073\/pnas.91.16.7792","article-title":"Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization","volume":"91","author":"Farci","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1093\/infdis\/173.4.822","article-title":"Effect of immune globulin on the prevention of experimental hepatitis C virus infection","volume":"173","author":"Krawczynski","year":"1996","journal-title":"J. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1084\/jem.20021756","article-title":"Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes","volume":"197","author":"Bartosch","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1073\/pnas.0832180100","article-title":"Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles","volume":"100","author":"Hsu","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"13963","DOI":"10.1128\/JVI.79.22.13963-13973.2005","article-title":"Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells","volume":"79","author":"Cai","year":"2005","journal-title":"J. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"9294","DOI":"10.1073\/pnas.0503596102","article-title":"Robust hepatitis C virus infection in vitro","volume":"102","author":"Zhong","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nm1268","article-title":"Production of infectious hepatitis C virus in tissue culture from a cloned viral genome","volume":"11","author":"Wakita","year":"2005","journal-title":"Nat. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"14199","DOI":"10.1073\/pnas.2335981100","article-title":"In vitro assay for neutralizing antibody to hepatitis C virus: Evidence for broadly conserved neutralization epitopes","volume":"100","author":"Bartosch","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1128\/JVI.79.10.6023-6034.2005","article-title":"Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection","volume":"79","author":"Lavillette","year":"2005","journal-title":"J. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1073\/pnas.0607026104","article-title":"Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C","volume":"104","author":"Pestka","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1084\/jem.20090766","article-title":"Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation","volume":"207","author":"Fofana","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/90968","article-title":"Hepatitis C virus replication in mice with chimeric human livers","volume":"7","author":"Mercer","year":"2001","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1002\/hep.22244","article-title":"Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain","volume":"47","author":"Vanwolleghem","year":"2008","journal-title":"Hepatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nm1698","article-title":"Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge","volume":"14","author":"Law","year":"2008","journal-title":"Nat. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/nature10168","article-title":"A genetically humanized mouse model for hepatitis C virus infection","volume":"474","author":"Dorner","year":"2011","journal-title":"Nature"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1128\/JVI.01872-07","article-title":"Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus","volume":"82","author":"Meunier","year":"2008","journal-title":"J. Virol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7408","DOI":"10.1073\/pnas.0504877103","article-title":"Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras","volume":"103","author":"Pietschmann","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1128\/JVI.78.1.187-196.2004","article-title":"Control of heterologous hepatitis C virus Infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response","volume":"78","author":"Rollier","year":"2004","journal-title":"J. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/hep.22465","article-title":"Hepatitis C virus envelope components alter localization of hepatocyte tight junction-associated proteins and promote occludin retention in the endoplasmic reticulum","volume":"48","author":"Benedicto","year":"2008","journal-title":"Hepatology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"8012","DOI":"10.1128\/JVI.00038-09","article-title":"Tight junction-associated protein occludin is required for a post-binding step in hepatitis C virus entry and infection","volume":"83","author":"Benedicto","year":"2009","journal-title":"J. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nature05654","article-title":"Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry","volume":"446","author":"Evans","year":"2007","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1128\/JVI.01888-08","article-title":"Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection","volume":"83","author":"Liu","year":"2009","journal-title":"J. Virol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1128\/JVI.01977-07","article-title":"The tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virus","volume":"82","author":"Meertens","year":"2008","journal-title":"J. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/nature07684","article-title":"Human occludin is a hepatitis C virus entry factor required for infection of mouse cells","volume":"457","author":"Ploss","year":"2009","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1126\/science.282.5390.938","article-title":"Binding of hepatitis C virus to CD81","volume":"282","author":"Pileri","year":"1998","journal-title":"Science"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1093\/emboj\/cdf529","article-title":"The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus","volume":"21","author":"Scarselli","year":"2002","journal-title":"EMBO J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1128\/jvi.68.3.1494-1500.1994","article-title":"Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses","volume":"68","author":"Shimizu","year":"1994","journal-title":"J. Virol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1006\/viro.1995.1196","article-title":"Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment","volume":"208","author":"Zibert","year":"1995","journal-title":"Virology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s007050050098","article-title":"Characterization of antibody response to hepatitis C virus protein E2 and significance of hypervariable region 1-specific antibodies in viral neutralization","volume":"142","author":"Zibert","year":"1997","journal-title":"Arch. Virol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1086\/655902","article-title":"Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins","volume":"202","author":"Ray","year":"2010","journal-title":"J. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1053\/jhep.2001.22175","article-title":"Mimotopes of the hepatitis C virus hypervariable region 1, but not the natural sequences, induce cross-reactive antibody response by genetic immunization","volume":"33","author":"Zucchelli","year":"2001","journal-title":"Hepatology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1006\/viro.1996.0497","article-title":"A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures","volume":"223","author":"Shimizu","year":"1996","journal-title":"Virology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s007050050559","article-title":"Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees","volume":"144","author":"Esumi","year":"1999","journal-title":"Arch. Virol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"15394","DOI":"10.1073\/pnas.93.26.15394","article-title":"Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein","volume":"93","author":"Farci","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1386-6346(00)00113-3","article-title":"Prevention of hepatitis C virus infection in a chimpanzee by vaccination and epitope mapping of antiserum directed against hypervariable region 1","volume":"19","author":"Goto","year":"2001","journal-title":"Hepatol. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1128\/jvi.67.7.3923-3930.1993","article-title":"Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus","volume":"67","author":"Kato","year":"1993","journal-title":"J. Virol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1073\/pnas.89.8.3468","article-title":"Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: Potential role in chronic HCV infections","volume":"89","author":"Weiner","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1053\/j.gastro.2006.12.008","article-title":"Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo","volume":"132","author":"Yoon","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1053\/j.gastro.2009.02.080","article-title":"Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus","volume":"136","author":"Dowd","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/jmv.10521","article-title":"Broadly cross-reactive mimotope of hypervariable region 1 of hepatitis C virus derived from DNA shuffling and screened by phage display library","volume":"71","author":"Zhang","year":"2003","journal-title":"J. Med. Virol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1093\/emboj\/17.13.3521","article-title":"Towards a solution for hepatitis C virus hypervariability: Mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants","volume":"17","author":"Puntoriero","year":"1998","journal-title":"EMBO J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1128\/JVI.01594-10","article-title":"Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization","volume":"85","author":"Prentoe","year":"2011","journal-title":"J. Virol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5751","DOI":"10.1128\/JVI.02200-09","article-title":"Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes","volume":"84","author":"Bankwitz","year":"2010","journal-title":"J. Virol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"11095","DOI":"10.1128\/JVI.79.17.11095-11104.2005","article-title":"Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein","volume":"79","author":"Owsianka","year":"2005","journal-title":"J. Virol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/hep.21088","article-title":"Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33","volume":"43","author":"Tarr","year":"2006","journal-title":"Hepatology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"12473","DOI":"10.1128\/JVI.01138-09","article-title":"Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus","volume":"83","author":"Broering","year":"2009","journal-title":"J. Virol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"6235","DOI":"10.1128\/JVI.73.8.6235-6244.1999","article-title":"Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81","volume":"73","author":"Flint","year":"1999","journal-title":"J. Virol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"8695","DOI":"10.1128\/JVI.00271-06","article-title":"Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding","volume":"80","author":"Owsianka","year":"2006","journal-title":"J. Virol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.1128\/JVI.00586-11","article-title":"Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step","volume":"85","author":"Sabo","year":"2011","journal-title":"J. Virol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Krey, T., d\u2019Alayer, J., Kikuti, C.M., Saulnier, A., Damier-Piolle, L., Petitpas, I., Johansson, D.X., Tawar, R.G., Baron, B., and Robert, B. (2010). The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1000762"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/375291a0","article-title":"The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution","volume":"375","author":"Rey","year":"1995","journal-title":"Nature"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"19450","DOI":"10.1073\/pnas.0809879105","article-title":"In vitro selection of a neutralization-resistant hepatitis C virus escape mutant","volume":"105","author":"Keck","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1099\/vir.0.83065-0","article-title":"Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33","volume":"88","author":"Tarr","year":"2007","journal-title":"J. Gen. Virol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1128\/JVI.02153-09","article-title":"Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies","volume":"84","author":"Dhillon","year":"2010","journal-title":"J. Virol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"10407","DOI":"10.1128\/JVI.74.22.10407-10416.2000","article-title":"Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes","volume":"74","author":"Hadlock","year":"2000","journal-title":"J. Virol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1099\/0022-1317-81-10-2451","article-title":"Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81","volume":"81","author":"Allander","year":"2000","journal-title":"J. Gen. Virol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"9986","DOI":"10.1128\/JVI.75.20.9986-9990.2001","article-title":"Mapping B-cell epitopes of hepatitis C virus E2 glycoprotein using human monoclonal antibodies from phage display libraries","volume":"75","author":"Bugli","year":"2001","journal-title":"J. Virol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1006\/viro.1998.9202","article-title":"Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties","volume":"249","author":"Habersetzer","year":"1998","journal-title":"Virology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"9224","DOI":"10.1128\/JVI.78.17.9224-9232.2004","article-title":"Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions","volume":"78","author":"Keck","year":"2004","journal-title":"J. Virol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"13199","DOI":"10.1128\/JVI.79.21.13199-13208.2005","article-title":"Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2","volume":"79","author":"Keck","year":"2005","journal-title":"J. Virol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1128\/JVI.02475-07","article-title":"Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies","volume":"82","author":"Keck","year":"2008","journal-title":"J. Virol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1099\/vir.0.83386-0","article-title":"Broadly neutralizing human monoclonal antibodies to Hepatitis C Virus E2 glycoprotein","volume":"89","author":"Owsianka","year":"2008","journal-title":"J. Gen. Virol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Wang, Y., Keck, Z., Saha, A., Xia, J., Conrad, F., Lou, J., Eckart, M., Marks, J.D., and Foung, S. (2011). Affinity maturation to improve human monoclonal antibody neutralization potency and breadth of reactivity against hepatitis C virus. J. Biol. Chem.","DOI":"10.1074\/jbc.M111.290783"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"10451","DOI":"10.1128\/JVI.05259-11","article-title":"Mapping a region of HCV E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations","volume":"85","author":"Keck","year":"2011","journal-title":"J. Virol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"7844","DOI":"10.1128\/JVI.00029-06","article-title":"A conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry","volume":"80","author":"Drummer","year":"2006","journal-title":"J. Virol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"16269","DOI":"10.1073\/pnas.0705522104","article-title":"Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus","volume":"104","author":"Johansson","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1128\/JVI.01986-07","article-title":"Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein","volume":"82","author":"Perotti","year":"2008","journal-title":"J. Virol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nm1698","article-title":"Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge","volume":"14","author":"Law","year":"2008","journal-title":"Nat. Med."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Mancini, N., Diotti, R.A., Perotti, M., Sautto, G., Clementi, N., Nitti, G., Patel, A.H., Ball, J.K., Clementi, M., and Burioni, R. (2009). Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes. PLoS One, 4.","DOI":"10.1371\/journal.pone.0008254"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"8101","DOI":"10.1128\/JVI.00127-07","article-title":"The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein","volume":"81","author":"Helle","year":"2007","journal-title":"J. Virol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"6067","DOI":"10.1128\/JVI.00252-08","article-title":"A point mutation leading to hepatitis C virus escape from neutralization by a monoclonal antibody to a conserved conformational epitope","volume":"82","author":"Keck","year":"2008","journal-title":"J. Virol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"8072","DOI":"10.1128\/JVI.00459-07","article-title":"Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization","volume":"81","author":"Falkowska","year":"2007","journal-title":"J. Virol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/BF00198849","article-title":"Association of hepatitis C virus in human sera with beta-lipoprotein","volume":"181","author":"Thomssen","year":"1992","journal-title":"Med. Microbiol. Immunol. (Berl.)"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"11905","DOI":"10.1128\/JVI.01548-10","article-title":"Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions","volume":"84","author":"Helle","year":"2010","journal-title":"J. Virol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"8449","DOI":"10.1073\/pnas.0703039104","article-title":"Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma","volume":"104","author":"Zhang","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"7537","DOI":"10.1073\/pnas.0902749106","article-title":"Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity","volume":"106","author":"Zhang","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"6919","DOI":"10.1128\/JVI.76.14.6919-6928.2002","article-title":"Characterization of low- and very-low-density hepatitis C virus RNA-containing particles","volume":"76","author":"Andre","year":"2002","journal-title":"J. Virol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Icard, V., Diaz, O., Scholtes, C., Perrin-Cocon, L., Ramiere, C., Bartenschlager, R., Penin, F., Lotteau, V., and Andre, P. (2009). Secretion of hepatitis C virus envelope glycoproteins depends on assembly of apolipoprotein B positive lipoproteins. PLoS One, 4.","DOI":"10.1371\/journal.pone.0004233"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"13783","DOI":"10.1128\/JVI.01091-07","article-title":"Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture","volume":"81","author":"Chang","year":"2007","journal-title":"J. Virol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1073\/pnas.0700760104","article-title":"Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins","volume":"104","author":"Huang","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1128\/JVI.01890-06","article-title":"Compensatory mutations in E1, p7, NS2 and NS3 enhance yields of cell culture-infectious inter-genotypic chimeric hepatitis C virus","volume":"81","author":"Yi","year":"2007","journal-title":"J. Virol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"18285","DOI":"10.1074\/jbc.M602706200","article-title":"High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI","volume":"281","author":"Dreux","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1128\/JVI.80.5.2418-2428.2006","article-title":"Association between hepatitis C virus and very-low-density lipoprotein (VLDL)\/LDL analyzed in iodixanol density gradients","volume":"80","author":"Nielsen","year":"2006","journal-title":"J. Virol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/hep.21959","article-title":"Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies","volume":"47","author":"Timpe","year":"2008","journal-title":"Hepatology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1099\/vir.0.006700-0","article-title":"CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells","volume":"90","author":"Witteveldt","year":"2009","journal-title":"J. Gen. Virol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1128\/JVI.01592-10","article-title":"Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission","volume":"85","author":"Brimacombe","year":"2011","journal-title":"J. Virol."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Baldick, C.J., Wichroski, M.J., Pendri, A., Walsh, A.W., Fang, J., Mazzucco, C.E., Pokornowski, K.A., Rose, R.E., Eggers, B.J., and Hsu, M. (2010). A novel small molecule inhibitor of hepatitis C virus entry. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1001086"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/jmv.20527","article-title":"Transmission in vitro of hepatitis C virus from persistently infected human B-cells to hepatoma cells by cell-to-cell contact","volume":"78","author":"Valli","year":"2006","journal-title":"J. Med. Virol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/3\/11\/2127\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:57:54Z","timestamp":1760219874000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/3\/11\/2127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,2]]},"references-count":100,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2011,11]]}},"alternative-id":["v3112127"],"URL":"https:\/\/doi.org\/10.3390\/v3112127","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,2]]}}}